iBio, Inc. (IBIO)
NYSEAMERICAN: IBIO · IEX Real-Time Price · USD
0.290
+0.010 (3.65%)
Nov 27, 2023, 4:00 PM EST - Market closed
iBio, Inc. Revenue
iBio, Inc. had revenue of $50.00K in the twelve months ending September 30, 2023, down -97.22% year-over-year. Revenue in the quarter ending September 30, 2023 was $50.00K.
Revenue (ttm)
$50.00K
Revenue Growth
-97.22%
P/S Ratio
162.92
Revenue / Employee
$1,923
Employees
26
Market Cap
8.15M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2023 | 0 | - | - |
| Jun 30, 2022 | 1.88M | -487.00K | -20.54% |
| Jun 30, 2021 | 2.37M | 733.00K | 44.75% |
| Jun 30, 2020 | 1.64M | -380.00K | -18.83% |
| Jun 30, 2019 | 2.02M | 1.57M | 354.50% |
| Jun 30, 2018 | 444.00K | 50.00K | 12.69% |
| Jun 30, 2017 | 394.00K | -554.00K | -58.44% |
| Jun 30, 2016 | 948.00K | -903.00K | -48.78% |
| Jun 30, 2015 | 1.85M | 1.65M | 802.93% |
| Jun 30, 2014 | 205.00K | -802.00K | -79.64% |
| Jun 30, 2013 | 1.01M | -270.00K | -21.14% |
| Jun 30, 2012 | 1.28M | 756.92K | 145.54% |
| Jun 30, 2011 | 520.08K | - | - |
| Jun 30, 2010 | 0 | - | - |
| Jun 30, 2009 | 1.18M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Acutus Medical | 19.66M |
| Guardion Health Sciences | 12.04M |
| Biotricity | 11.11M |
| Syra Health | 5.71M |
| Benitec Biopharma | 75.00K |
IBIO News
- 12 hours ago - iBio Announces Reverse Stock Split - GlobeNewsWire
- 26 days ago - iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific - GlobeNewsWire
- 2 months ago - iBio Explains Recent Filing of Registration Statement - GlobeNewsWire
- 2 months ago - iBio Announces Filing of 2023 Annual Report on SEC Form 10-K - GlobeNewsWire
- 2 months ago - iBio Announces Amendment to Credit Agreement with Woodforest - GlobeNewsWire
- 3 months ago - iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development - GlobeNewsWire
- 5 months ago - iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth - GlobeNewsWire
- 6 months ago - iBio Forges Research Collaboration with the National Institutes of Health - GlobeNewsWire